Infant Bacterial Therapeutics AB (IBT B):企業の財務・戦略的SWOT分析

【英語タイトル】Infant Bacterial Therapeutics AB (IBT B) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C14935)・商品コード:DATA904C14935
・発行会社(調査会社):GlobalData
・発行日:2019年3月
・ページ数:25
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Infant Bacterial Therapeutics AB (IBT), a subsidiary of BioGaia AB is a pharmaceutical company that develops drugs influencing the human infant microbiome to treat rare diseases in premature infants. Its pipeline product candidates include IBP-9414, containing the active substance Lactobacillus reuteri, co-evolved human bacterial strain derived from human breast milk, used for the prevention of Necrotizing enterocolitis (NEC); and IBP-1016, a drug candidate used for the treatment of gastroschisis, a severe disease in infants. The company develops pharmaceutical drug candidates for gastrointestinal neonatal condition that causes mucosal injury, necrosis, perforation in the intestinal tracts of infants and death. It operates through a network of neonatologists and research groups. IBT is headquartered in Stockholm City, Sweden.

Infant Bacterial Therapeutics AB Key Recent Developments

Feb 05,2019: Infant Bacterial Therapeutics names Anna Olsson as Director of Clinical Development
Nov 21,2018: The Phase 3 study protocol is modified after IBT’s meeting with the FDA
Nov 14,2018: Infant Bacterial Therapeutics interim management statement, January 1 – September 30, 2018
Sep 10,2018: TOPC : Nasdaq Stockholm Welcomes Infant Bacterial Therapeutics to the Main Market[Newswire : FS - GNW RSS]
Aug 16,2018: Infant Bacterial Therapeutics interim management statement, January 1 – June 30, 2018

This comprehensive SWOT profile of Infant Bacterial Therapeutics AB provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Infant Bacterial Therapeutics AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Infant Bacterial Therapeutics AB – Key Information
Infant Bacterial Therapeutics AB – Overview
Infant Bacterial Therapeutics AB – Key Employees
Infant Bacterial Therapeutics AB – Key Employee Biographies
Infant Bacterial Therapeutics AB – Key Operational Heads
Infant Bacterial Therapeutics AB – Major Products and Services
Infant Bacterial Therapeutics AB – History
Infant Bacterial Therapeutics AB – Company Statement
Infant Bacterial Therapeutics AB – Locations And Subsidiaries
Infant Bacterial Therapeutics AB – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Infant Bacterial Therapeutics AB – Business Description
Infant Bacterial Therapeutics AB – Corporate Strategy
Infant Bacterial Therapeutics AB – SWOT Analysis
SWOT Analysis – Overview
Infant Bacterial Therapeutics AB – Strengths
Infant Bacterial Therapeutics AB – Weaknesses
Infant Bacterial Therapeutics AB – Opportunities
Infant Bacterial Therapeutics AB – Threats
Infant Bacterial Therapeutics AB – Key Competitors

Section 3 – Company Financial Performance Charts

Infant Bacterial Therapeutics AB – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Infant Bacterial Therapeutics AB, Key Information
Infant Bacterial Therapeutics AB, Key Ratios
Infant Bacterial Therapeutics AB, Share Data
Infant Bacterial Therapeutics AB, Major Products and Services
Infant Bacterial Therapeutics AB, History
Infant Bacterial Therapeutics AB, Key Employees
Infant Bacterial Therapeutics AB, Key Employee Biographies
Infant Bacterial Therapeutics AB, Key Operational Heads
Infant Bacterial Therapeutics AB, Other Locations
Infant Bacterial Therapeutics AB, Subsidiaries
Infant Bacterial Therapeutics AB, Key Manufacturing facilities
Infant Bacterial Therapeutics AB, Key Competitors
Infant Bacterial Therapeutics AB, SWOT Analysis
Infant Bacterial Therapeutics AB, Ratios based on current share price
Infant Bacterial Therapeutics AB, Annual Ratios
Infant Bacterial Therapeutics AB, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Infant Bacterial Therapeutics AB, Performance Chart
Infant Bacterial Therapeutics AB, Ratio Charts

★調査レポート[Infant Bacterial Therapeutics AB (IBT B):企業の財務・戦略的SWOT分析] (コード:DATA904C14935)販売に関する免責事項を必ずご確認ください。
★調査レポート[Infant Bacterial Therapeutics AB (IBT B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆